ALLIANZ-WORLDWIDE-CARE
Allianz Worldwide Care has announced the launch of security and risk management services for multinationals. The corporate assistance solution has been designed to cater for companies with a globally-mobile base of employees and organisations that operate in high-risk or unstable areas.
The new services include a wide range of tools that offer detailed country risk assessments, pinpoint the geographic location of employees during a crisis, organise ‘meet and greet’ and ‘check-in’ security services when travelling in high-risk locations, and provide detailed cultural awareness programmes.
Alexis Obligi, Director of Sales and Marketing at Allianz Worldwide Care, said: “These services are designed to meet the needs of global organisations for whom it’s impossible to predict when and where a crisis might occur. With the ever-present threat of natural disaster, civil unrest or terrorist activity, real-time information about potential risks has never been more important. Our service enhancements are designed to give our clients a comprehensive range of solutions to ensure the safety and well-being of their workers.”
The security features of the service have been reinforced through a new partnership with red24, a global leader in crisis and risk management. Through this partnership, Allianz offers clients access to a global network of expert security specialists, providing real-time destination risk reports and analysis. This gives organisations a comprehensive overview of the security risks involved when moving or travelling to potentially volatile locations, with full support from a 24/7 emergency assistance team.
The new services reflect the proactive approach Allianz takes to corporate assistance, and involves working closely with clients, including looking at the travel protocols they have in place, reviewing their crisis management plans, ensuring an organisation has comprehensive oversight of employee safety and well-being whilst abroad, and awareness of what support is in place in the event of a medical, travel or security emergency.
Alexis Obligi said: “The newly enhanced services are designed to help organisations pre-emptively mitigate security risks to their business, their employees and their families, wherever they are in the world. Our full range of corporate assistance and risk management solutions includes a fully integrated health, travel, security, occupational health and employee assistance programme.”
Allianz Corporate Assistance Services are supported by multi-lingual, 24/7 emergency support and on-the-ground assistance. Clients are offered the flexibility to select the services and support they require.
About Allianz Worldwide Care
Allianz Worldwide Care is the international health and life insurance division of Allianz Worldwide Partners which serves more than 250 million beneficiaries in 34 countries and is part of the Allianz Group. Allianz Worldwide Care provides insurance solutions for health, life and disability to clients and insurance partners on a global scale. Our focus is on earning and maintaining client loyalty by providing a market leading product range, level of service and support. With a client base that includes many of the Fortune Global 500 companies, Allianz Worldwide Care continues to build a reputation for service excellence in international healthcare. www.allianzworldwidecare.com
About red24
red24 is a crisis management assistance company delivering a range of products and services to businesses, organisations and individuals around the world. red24 has an unparalleled reputation for assisting clients in minimising risks to their personnel, operations and profitability.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005042/en/
Contact:
Rachel Sherry (Grayling on behalf of Allianz Worldwide Care)
T 087
6622111
or
George Eddy (Grayling on behalf of Allianz
Worldwide Care)
T +44 (0) 207 932 1885
george.eddy@grayling.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom